R.p.scherer Technologies, Inc.

Alk-Abello A/s

Catalent U.k. Swindon Zydis Limited

Nordmark Pharma Gmbh

Lisa Garrett

Susan Gerrard Banbury

Henrik Hugo Jacobi

Michael Hall

Christian Gauguin Houghton

Stig Aasmul-Olsen

Desmond Yik Teng Wong

Annette Roemmelmayer Lundegaard

Lise Lund Maerkedahl

Jan Sondergaard Andersen

Kerry Mallindine

Owen James Murray

Rosaleen McLaughlin

Yik Teng Wong

Richard Fuhrherr

Jan Lüdemann

Niamh Barrat

Emilie Masto

Jan Ludemann

Karolyn Tapper

The present invention relates to an orodispersible tablet characterized in that it includes burlulipase. It also relates to liquid pharmaceutical compositions that contain solutions of such orodispersible tablets in water or other beverages. It relates to drugs that contain or consist of such orodispersible tablets or solutions. In particular, it relates to such drugs that are suitable for treating digestive problems, in particular exocrine pancreatic insufficiency used to treat digestive problems. In particular, they are for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients and for treatment of exocrine pancreatic insufficiency in pediatric patients.

Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom

Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.

Lyophilized pharmaceutical compositions for vaginal delivery

The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

Allergen dosage form

Growing community of inventors

Swindon, United Kingdom

Lisa Garrett